8-K - Monopar Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Monopar Therapeutics Inc. announced its fourth quarter and full-year 2025 financial results, reporting a net loss of $5.2 million for Q4 2025 and $13.7 million for the full year, and provided a business update including plans to submit an NDA for ALXN1840 in mid-2026. The company ended 2025 with $140.4 million in cash and expects its funds to support operations through at least December 31, 2027.

Key Takeaways

1Net loss for Q4 2025 was $5.2 million ($0.61 per share), compared to $10.9 million ($2.23 per share) for Q4 2024.

2Net loss for full-year 2025 was $13.7 million ($1.85 per share), compared to $15.6 million ($4.11 per share) for full-year 2024.

3Cash, cash equivalents and short-term investments as of December 31, 2025, were $140.4 million, with funds expected to support operations through at least December 31, 2027.

4Monopar plans to submit a New Drug Application (NDA) for ALXN1840 for Wilson disease to the FDA in mid-2026.

5R&D expenses for Q4 2025 were $3.9 million, down from $9.9 million in Q4 2024, primarily due to the absence of one-time ALXN1840 in-licensing expenses.

6G&A expenses for Q4 2025 were $2.2 million, up from $1.2 million in Q4 2024, primarily due to higher personnel and patent legal fees.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (

Financial Results

9.01

Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated March 27, 2026 104 Cover Page Interactive Data File (embedded within the Inli

Exhibits Only

Source Document

Results of Operations

Fourth Quarter and Full Year 2025

Metric	Value	Prior Period
Net Loss	$5.20	$10.90
Diluted EPS	$-0.61	$-2.23
Net Loss	$13.70	$15.60
Diluted EPS	$-1.85	$-4.11

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1